{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': 'Blanchardstown Corporate Park',
 'address2': 'Block 10-1 Ballycoolin',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.34,
 'askSize': 3000,
 'averageDailyVolume10Day': 529375,
 'averageVolume': 918077,
 'averageVolume10days': 529375,
 'beta': 1.138781,
 'beta3Year': None,
 'bid': 8.38,
 'bidSize': 2200,
 'bookValue': 0.691,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dublin',
 'companyOfficers': [],
 'country': 'Ireland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8.42,
 'dayLow': 7.83,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -37.375,
 'enterpriseToRevenue': 9.04,
 'enterpriseValue': 497385184,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '353 1 526 1077',
 'fiftyDayAverage': 8.286,
 'fiftyTwoWeekHigh': 13.49,
 'fiftyTwoWeekLow': 1.82,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 39202223,
 'forwardEps': -0.75,
 'forwardPE': -11.12,
 'fromCurrency': None,
 'fullTimeEmployees': 50,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.08135,
 'heldPercentInstitutions': 0.39867002,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/avadel.com',
 'longBusinessSummary': 'Avadel Pharmaceuticals plc operates as a specialty '
                        'pharmaceutical company in the United States, France, '
                        'and Ireland. The company primarily develops FT218, '
                        'which is in a Phase 3 clinical trial for the '
                        'treatment of narcolepsy patients suffering from '
                        'excessive daytime sleepiness (EDS) and cataplexy. It '
                        'also markets three sterile injectable drugs used in '
                        'the hospital setting, including Akovaz that is '
                        'indicated for the treatment of clinically important '
                        'hypotension occurring in the setting of anesthesia; '
                        'Bloxiverz, a cholinesterase inhibitor indicated for '
                        'the reversal of the effects of non-depolarizing '
                        'neuromuscular blocking agents after surgery; and '
                        'Vazculep, a phenylephrine hydrochloride injection '
                        'indicated for the treatment of clinically important '
                        'hypotension. The company was formerly known as Flamel '
                        'Technologies SA and changed its name to Avadel '
                        'Pharmaceuticals PLC in January 2017. Avadel '
                        'Pharmaceuticals plc was incorporated in 2015 and is '
                        'headquartered in Dublin, Ireland.',
 'longName': 'Avadel Pharmaceuticals plc',
 'market': 'us_market',
 'marketCap': 484795872,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_28567',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -21073000,
 'nextFiscalYearEnd': 1640908800,
 'open': 8,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.85,
 'phone': '353 1 485 1200',
 'previousClose': 8.01,
 'priceHint': 2,
 'priceToBook': 12.069465,
 'priceToSalesTrailing12Months': 8.811106,
 'profitMargins': -0.383,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8.42,
 'regularMarketDayLow': 7.83,
 'regularMarketOpen': 8,
 'regularMarketPreviousClose': 8.01,
 'regularMarketPrice': 8,
 'regularMarketVolume': 1261636,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 58129000,
 'sharesPercentSharesOut': 0.088999994,
 'sharesShort': 5171508,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5138282,
 'shortName': 'Avadel Pharmaceuticals plc',
 'shortPercentOfFloat': None,
 'shortRatio': 8,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'AVDL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.55,
 'twoHundredDayAverage': 8.249208,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'eed4625d-e4bb-3438-b887-c6091808e157',
 'volume': 1261636,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.avadel.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '15'}